Seattle Genetics Inc. (SGEN) and Its Peers Financial Results Comparison

As Biotechnology company, Seattle Genetics Inc. (NASDAQ:SGEN) is competing with its peers based on the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Institutional and Insider Ownership

0% of Seattle Genetics Inc.’s shares are held by institutional investors. Comparatively, 50.88% of all Biotechnology’s companies shares are held by institutional investors. On other hand Seattle Genetics Inc. has 0.9% of its shares held by company insiders and an average of 8.18% insiders ownership for its rivals.

Profitability

Table 1 has Seattle Genetics Inc. and its rivals’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Seattle Genetics Inc. -34.01% -13.80% -11.80%
Industry Average 1,464.25% 88.44% 21.62%

Valuation & Earnings

The following data compares Seattle Genetics Inc. and its rivals’ net profit, valuation and top-line revenue.

Net Income Gross Revenue Price/Earnings Ratio
Seattle Genetics Inc. 222.69M 654.70M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 shows breakdown of recent ratings for Seattle Genetics Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seattle Genetics Inc. 0 1 2 2.67
Industry Average 1.17 1.78 2.01 2.68

Seattle Genetics Inc. currently has a consensus target price of $85.67, suggesting a potential upside of 25.82%. The rivals have a potential upside of 173.20%. Seattle Genetics Inc.’s strong average rating and high possible upside, looks like is making equities research analysts believe that the business is more favorable than its rivals.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Seattle Genetics Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seattle Genetics Inc. -3.08% -0.49% -22.02% -9.12% 5.9% 13.36%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Seattle Genetics Inc.’s stock price has smaller growth than the average for its rivals.

Liquidity

The Current Ratio and a Quick Ratio of Seattle Genetics Inc. are 3.7 and 3.3. Competitively, Seattle Genetics Inc.’s rivals have 7.68 and 7.52 for Current and Quick Ratio. Seattle Genetics Inc.’s competitors have better ability to pay short and long-term obligations than Seattle Genetics Inc.

Risk & Volatility

Seattle Genetics Inc. is 119.00% more volatile than S&P 500 because the company has a beta of 2.19. In other hand, Seattle Genetics Inc.’s peers have beta of 1.70 which is 70.08% more volatile than S&P 500.

Dividends

Seattle Genetics Inc. does not pay a dividend.

Summary

On 4 of the 4 factors Seattle Genetics Inc.’s competitors beat Seattle Genetics Inc.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.